Avrobio Plots Plan B After Fabry Disease Gene Therapy Problems

Lead Candidate Shelved

 
• By Andrew McConaghie
  
DNA helix
The company's ex vivo lentiviral gene therapy platform has hit an obstacle in Fabry disease - but it hopes other rare diseases will deliver. • Source: Alamy
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from R&D

More from Scrip